Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progressive Supranuclear Palsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Progressive Supranuclear Palsy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-001635-12 Sponsor Protocol Number: M15-562 Start Date*: 2017-11-23
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy
    Medical condition: Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013097-40 Sponsor Protocol Number: NP031112-08B02 Start Date*: 2009-10-30
    Sponsor Name:Noscira S.A.
    Full Title: A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in t...
    Medical condition: Mild to Moderate Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036813 Progressive supranuclear palsy LLT
    12.0 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003911-90 Sponsor Protocol Number: RT001-013 Start Date*: 2021-03-31
    Sponsor Name:Retrotope, Inc
    Full Title: A RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY TO ASSESS EFFICACY, LONG TERM SAFETY AND TOLERABILITY OF RT001 IN SUBJECTS WITH PROGRESSIVE SUPRANUCLEAR PALSY.
    Medical condition: Progressive supranuclear palsy (PSP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) SK (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007520-26 Sponsor Protocol Number: PROSPERA (Rasagiline) Start Date*: 2010-06-24
    Sponsor Name:Klinikum der Universität München
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)
    Medical condition: Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    12.0 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001590-16 Sponsor Protocol Number: M15-563 Start Date*: 2019-07-02
    Sponsor Name:AbbVie Deutschland
    Full Title: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
    Medical condition: Progressive Supranuclear Palsy (PSP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002554-21 Sponsor Protocol Number: 251PP301 Start Date*: 2017-07-21
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants with Progressive Supranuclear Palsy
    Medical condition: Progressive supranuclear palsy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Prematurely Ended) GR (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003740-23 Sponsor Protocol Number: AB13004 Start Date*: 2015-02-04
    Sponsor Name:AB Science
    Full Title: A prospective, multicentre, randomised, double-blind, placebo-controlled, parallel groups, phase 2b/3 study to compare the efficacy and safety of masitinib versus placebo in the treatment of patien...
    Medical condition: Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019159-23 Sponsor Protocol Number: AL-108-231 Start Date*: 2010-11-08
    Sponsor Name:Allon Therapeutics Inc
    Full Title: A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy.
    Medical condition: Progressive Supranuclear Palsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000422-38 Sponsor Protocol Number: PET_imaging_of_Tau Start Date*: 2014-09-19
    Sponsor Name:Skåne University Hospital, Region Skåne
    Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
    Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    17.0 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    17.0 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    17.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    17.0 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    17.0 10029205 - Nervous system disorders 10012267 Dementia PT
    17.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    17.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000506-34 Sponsor Protocol Number: EMERA006 Start Date*: 2019-02-04
    Sponsor Name:NBMI Science Ltd.
    Full Title: EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear...
    Medical condition: PSP or MSA
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000094-36 Sponsor Protocol Number: BioFINDER_2 Start Date*: 2017-03-31
    Sponsor Name:Skåne University Hospital
    Full Title: The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders
    Medical condition: Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cogni...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    19.1 10029205 - Nervous system disorders 10012267 Dementia PT
    19.1 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    19.1 10029205 - Nervous system disorders 10028037 Movement disorders (incl parkinsonism) HLGT
    19.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    19.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    19.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    19.1 10029205 - Nervous system disorders 10048598 Cognitive disorders LLT
    19.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    19.1 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    19.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    19.1 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    19.1 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005915-13 Sponsor Protocol Number: TRx-014-002 Start Date*: 2006-07-12
    Sponsor Name:TauRx Therapeutics PTE Ltd
    Full Title: An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes
    Medical condition: Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potent...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012267 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003363-64 Sponsor Protocol Number: 13/0384 Start Date*: 2014-04-03
    Sponsor Name:University College London
    Full Title: A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease.
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006166-42 Sponsor Protocol Number: RIVA Start Date*: 2007-07-17
    Sponsor Name:University of Tuebingen
    Full Title: Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese - offene, prospektive Phase II-Studie -
    Medical condition: Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with hardly any therapeutical option to ameliorate the course of the disease. Results of first trials with physostigmine and don...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000574-40 Sponsor Protocol Number: PSP-CoQ10 Start Date*: 2006-04-24
    Sponsor Name:Kompetenznetz Parkinson e.V.
    Full Title: Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon®
    Medical condition: PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 10...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005539-10 Sponsor Protocol Number: MRZ60201_3090_1 Start Date*: 2014-04-29
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two...
    Medical condition: Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10017947 - Gastrointestinal disorders 10039424 Salivary hypersecretion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-002988-30 Sponsor Protocol Number: PROFIL-2088-SIM-0032-I Start Date*: 2023-04-19
    Sponsor Name:Klinikum rechts der Isar der Technischen Universität München
    Full Title: Double-blind, randomised, prospective, placebo controlled parallel group phase II study to investigate the effect of glycerol phenylbutyrate (GPB) on neurofilament light chain (NfL) levels in patie...
    Medical condition: Corticobasal Syndrome (CBS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10078208 Corticobasal degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003473-94 Sponsor Protocol Number: UCL-2016-121 Start Date*: 2019-05-20
    Sponsor Name:Cliniques Universitaires Saint-Luc
    Full Title: Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms.
    Medical condition: Alzheimer’s disease (AD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002227-13 Sponsor Protocol Number: ACP-103-045 Start Date*: 2018-02-04
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
    Medical condition: Hallucinations and Delusions Associated With Dementia-related Psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012295 Dementia of the Alzheimer's type, with delusions PT
    20.0 100000004873 10019077 Hallucinations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) SK (Prematurely Ended) BG (Completed) ES (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005761-23 Sponsor Protocol Number: CTD-TCNPC-201 Start Date*: 2016-09-26
    Sponsor Name:Cyclo Therapeutics, Inc.
    Full Title: A Phase I/II study to evaluate the safety and pharmacokinetics of intravenous Trappsol Cyclo (HP-β-CD) in patients with Niemann-Pick disease type C (NPC-1) and the pharmacodynamic effects of treatm...
    Medical condition: Niemann-Pick disease type C
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10029403 Niemann-Pick disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) IT (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:50:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA